- Exenatide acetate
-
- $1.00 / 1g
-
2024-04-23
- CAS:141732-76-5
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 100kg
- Exenatide acetate
-
- $1.00 / 1g
-
2024-04-23
- CAS:141732-76-5
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 100kg
- Exenatide Acetate
-
- $30.00 / 1box
-
2024-04-22
- CAS:141732-76-5
- Min. Order: 1box
- Purity: 98%
- Supply Ability: 5000box
|
| | Exenatide acetate Basic information |
| | Exenatide acetate Chemical Properties |
| Melting point | >209°C (dec.) | | storage temp. | Refrigerator, under inert atmosphere | | solubility | Acetonitrile (Slightly), Water (Slightly) | | form | Solid | | color | White to Off-White | | Sequence | H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 | | CAS DataBase Reference | 141732-76-5(CAS DataBase Reference) |
| | Exenatide acetate Usage And Synthesis |
| Chemical Properties | Exenatide acetate is White Solid | | Uses | Application of exenatide acetate causes an increase in acinar cAMP without stimulating amylase release. As an incretin mimetic, exenatide acetate acts as agonist of the glucagon-like peptide-1 (GLP-1) receptor. As GLP-1, though with prolonged activity, exenatide acetate augments the postprandial production of insulin and suppresses secretion of glucagon. For this reason, exenatide acetate has found use as a medication of diabetes II. | | Uses | A 39-amino acid peptide originally isolated from the salivary glands of the Gila monster (Heloderma suspectum), differs from exendin-3 only in two positions close to the N-terminus. Application of exenatide causes an increase in acinar cAMP without stimulating amylase release. As an incretin mimetic, exenatide acts as agonist of the glucagon-like peptide-1 (GLP-1) receptor. As GLP-1, though with prolonged activity, exenatide augments the postprandial production of insulin and suppresses secretion of glucagon. For this reason, exenatide has found use as a medication of diabetes II. | | Clinical Use | 39-peptide known as an incretin mimetic;
an agonist of glucagon-like peptide-1,
used adjunctively in type II diabetes
mellitus. | | Drug interactions | Potentially hazardous interactions with other drugs
Anticoagulants: possibly enhances anticoagulant
effect of warfarin.
Other nephrotoxins: avoid concomitant use. | | Metabolism | Exenatide is eliminated through the kidneys by
glomerular filtration followed by proteolytic degradation. |
| | Exenatide acetate Preparation Products And Raw materials |
|